EmayGene
Latest round
- Angel
Last raised
- Jan 2022
Total raised
- Undisclosed
Investors
- 1
About EmayGene
Established in 2021 and based in Shanghai, China, Shanghai Weimei Gene Technology operates as a gene therapy drug developer that provides gene therapy and drug. The company was incubated by the iHuman Institute of ShanghaiTech University. The company provides gene therapy and drug for patients with hearing diseases. The business of the company includes development, production and clinical application of gene therapy drugs. it focuses on cell function and adeno-associated virus. The company's products include AAV-inner ear (AAV-ie).
Who invested in EmayGene
1 investor across 1 round
See all investors in EmayGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Jan 7, 2022
Amount
Undisclosed
Investors
Questions about EmayGene
Who invested in EmayGene?
EmayGene has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EmayGene raised?
EmayGene has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did EmayGene last raise money?
EmayGene's most recent round on record is a Angel, in Jan 2022.
What does EmayGene do?
Established in 2021 and based in Shanghai, China, Shanghai Weimei Gene Technology operates as a gene therapy drug developer that provides gene therapy and drug.
Where is EmayGene headquartered?
EmayGene is headquartered in Shanghai, China.
Which VCs invest in companies like EmayGene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at EmayGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like EmayGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.